Farnesylation, which is catalyzed by farnesyltransferase, promotes membrane association of the modified protein and protein-protein interactions, and plays an important role in a number of physiological processes of pathogenic fungi, including stress response, environmental adaption and virulence. Lonafarnib is an orally bioavailable nonpeptide tricyclic farnesyltransferase inhibitor with excellent pharmacokinetic and safety profile. In the present study, we investigated the in vitro activities of lonafarnib alone or combined with azoles, including itraconazole, voriconazole, and posaconazole, against 22 strains of Aspergillus spp. and 18 strains of Exophiala dermatitidis via broth microdilution checkerboard technique. Lonafarnib alone was inactive against all isolates tested. However, synergistic effects between lonafarnib and itraconazole were observed in 86% Aspergillus strains and 94% E. dermatitidis strains. In addition, lonafarnib/posaconazole combination also exhibited synergism against 59% of Aspergillus strains and 100% E. dermatitidis strains. However, synergistic effects of lonafarnib/voriconazole were only observed in 32% Aspergillus strains and 28% E. dermatitidis strains. The effective working ranges of lonafarnib were 2-4 μg/ml and 1-4 μg/ml against Aspergillus isolates and E. dermatitidis isolates, respectively. No antagonism was observed in all combinations. This study demonstrated that lonafarnib could enhance the in vitro antifungal activity of itraconazole, posaconazole and voriconazole against Aspergillus spp. and E. dermatitidis, suggesting that azoles, especially itraconazole and posaconazole, combined with farnesyltransferase inhibitor might provide a potential strategy to the management of Aspergillus and Exophiala infections. However, further studies are warranted to 
Introduction
Invasive fungal infection has emerged as a growing threat for human health, paralleling the increase in the number of immunocompromised patients. Invasive aspergillosis is the most common mould infection in humans with high mortality, 1 while opportunistic Exophiala spp. infections are also being increasingly recognized. E. dermatitidis is one of the most common cause of chromoblastomycosis and the leading cause of severe neurotropic phaeohyphomycosis. 2 The management is still challenging despite the expansion of antifungal strategies in recent years. 3 Azole resistance has been increasingly reported among Aspergillus isolates. 4 Additionally, non-fumigatus Aspergillus spp. with less susceptibility to available antifungal agents constitute a significant proportion of invasive aspergillosis. 5 As for Exophiala spp. infection, success rate was only 40-70% despite in vitro studies revealed favorable antifungal activities of most available antifungal agents. [6] [7] [8] Thus, there is an increasing need for novel antifungal approaches. Farnesylation, a posttranslational modification catalyzed by farnesyltransferase, occurs by covalent addition of farnesyl to conserved cysteine residues at or near the Cterminus of protein. 9 The effect of farnesylation is to promote membrane association of the modified protein and protein-protein interactions, which plays an important role in a number of physiological processes of pathogenic fungi, such as stress responses and environmental adaption. 10, 11 In the human fungal pathogen Cryptococcus neoformans, studies have demonstrated that farnesylation was required for cellular adaptation to stress, as well as full virulence in animal infection models. 12, 13 It has also been reported that inhibition of farnesyltransferase by several farnesyltransferase inhibitors (FTIs) exhibited C. neoformans fungicidal activity and manumycin A was found to kill fungal cells rapidly (<4 h) with minimum inhibitory concentrations (MICs) close to those for amphotericin B.
14 In a similar experiment, the inhibition of protein farnesylation in Candida albicans blocked the development of yeast to hyphae. 15 Our previous study also revealed that farnesylation was essential for cell growth of A. fumigatus, 16 and manumycin A had inhibition activity against Aspergillus spp. and Candida spp., albeit at high MICs. 17 In light of this, it is exciting to speculate that pharmacological interference between conventional antifungal agents with FTI might make a more effective treatment for fungal infections.
In the present study, the potential effects of lonafarnib, a nonpeptide tricyclic FTI, alone and combined with conventional antifungal agents against Aspergillus spp. and E. dermatitidis were investigated.
Methods

Fungal strains
A total of 40 clincial isolates were studied, including 12 strains of A. fumigatus, eight strains of A. flavus, two strains of A. terreus, and 18 strains of E. dermatitidis. Fungal identification was determined by microscopic morphology and by molecular sequencing of the internal transcribed spacer (ITS) ribosomal DNA (rDNA). For identification of Aspergillus spp., additional molecular sequence of β-tubulin and calmodulin was required. C. parapsilosis ATCC 22019 was included to ensure quality control.
Antifungals and chemical agents
All tested drugs including lonafarnib, itraconazole (ITC), voriconazole (VRC), and posaconazole (POS) were purchased in powder form from MedChem Express, Shanghai, China and prepared as outlined in the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method M38-A2 (Clinical and Laboratory Standards Institute, 2008). 18 The working concentration ranges were 0.25-16 μg/ml for lonafarnib and 0.03-4 μg/ml for all azoles, respectively.
Inoculum preparation
Conidia harvested from cultures grown for 7 days on Sabouraud dextrose agar were suspended in sterile distilled water containing 0.03% Triton and diluted to a concentration of 1-5 × 10 6 spores/ml, which were than diluted 100 times in RPMI-1640 to achieve a two-fold suspension more concentrated than the density needed or to approximately 1-5 × 10 4 spores/ml.
18
In vitro antifungal activity of individual tested agents
The individual MICs of lonafarnib, ITC, VRC, and POS were determined according to M38-A2 method. 18 The 96-well plate was inoculated with 100 μl of the inoculum suspension prepared and 100 μl of the serial diluent of tested drugs. Interpretation of results was performed after incubation at 35
• C for 48 h for Aspergillus spp. and 72 h for Exophiala spp., respectively. The MICs were determined as the lowest concentration resulting in complete inhibition of growth. 18 All tests were performed in triplicate.
In vitro interactions of lonafarnib and azoles
The interactions between lonafarnib and azoles against all strains were tested via microdilution chequerboard technique. As described, a 50 μl of lonafarnib with serial dilutions were inoculated in horizontal direction, and another 50 μl of azoles with serial dilutions were inoculated in vertical direction on the 96-well plate, which contained 100 μl prepared inoculum suspension. Interpretation of results was performed after incubation at 35
• C for 48 h for
Aspergillus spp. and 72 h for Exophiala spp., respectively. The interaction of lonafarnib with azoles referred to the fractional inhibitory concentration index (FICI), which was classified as follows: FICI of ≤0.5, synergy; FICI of >0.5 to ≤4, no interaction (indifference); FICI of >4, antagonism. 19 All tests were performed in triplicate.
Results
In vitro antifungal activities of individual tested agent
The MIC ranges of individual tested drugs against Aspergillus isolates were > 16 μg/ml, 0.5-1 μg/ml, 0.25-1 μg/ml, and 0.5-1 μg/ml, for lonafarnib, ITC, VRC, and POS, respectively ( Table 1 ). The MIC ranges against E. dermatitidis were > 16 μg/ml, 0.5-1 μg/ml, 0.5 μg/ml, and 0.5-1 μg/ml, for lonafarnib, ITC, VRC, and POS, respectively (Table 2 ).
In vitro interactions between lonafarnib and azoles
When lonafarnib was combined with ITC, the MICs of lonafarnib and ITC against Aspergillus spp. decreased to 3) . Similarly, the lonafarnib/ITC combination also showed favorable synergism against 17 (94%) strains of E. dermatitidis, where the MIC ranges of lonafarnib and ITC decreased to 1-4 μg/ml and 0.06-0.25 μg/ml, respectively (Table 2 and 3) . When lonafarnib was combined with POS, synergism was observed in all E. dermatitidis isolates and 59% strains of Aspergillus spp., including seven strains of A. fumigatus, five strains of A. flavus, and one strain of A. terreus, as shown in Table 1 -3. The MIC ranges of lonafarnib and POS against E. dermatitidis and Aspergillus isolates decreased to 1-4 μg/ml, 0.03-0.125 μg/ml, and 2-4 μg/ml, 0.125-0.25 μg/ml, respectively.
When lonafarnib was combined with VRC, synergy was observed in only four strains of E. dermatitidis and seven strains of Aspergillus spp., including two strains of A. fumigatus, four strains of A. flavus, and one strain of A. terreus. The effective working ranges of lonafarnib and VRC in this combination were 2-4 μg/ml and 0.06-0,125 μg/ml, respectively (Table 1-3) .
No antagonism was observed in all combinations.
Discussion
FTIs were originally designed to be anticancer agents. However, recent studies have indicated that farnesyltransferase could also be an effective target against infectious diseases such as hepatitis D infection, trypanosomiasis, malaria, toxoplasmosis, and leishmaniasis. 9 Previous studies have also revealed farnesyltransferase as an interesting target for pathogenic fungi 12, 16 and demonstrated the antifungal activities of some FTIs against several pathogenic fungi. 14, 17 However, little is known about the drug interactions between FTIs and conventional antifungal agents.
In this study, we evaluated the interactions between lonafarnib, an orally bioavailable nonpeptide tricyclic FTI, and azoles that commonly used in clinic against Aspergillus spp. and E. dermatitidis. In contrast to previous studies that showed fungicidal activities of FTIs against some pathogenic fungi, 14 the results of the present study revealed that lonafarnib alone was inactive against all Aspergillus spp. and E. dermatitidis isolates tested. Nevertheless, in the aspect of drug interactions, we found favorable synergistic effects between lonafarnib and ITC (90%) or POS (78%). The drug interaction profiles were comparable between the two species tested. Synergism was most often seen between lonafarnib and ITC or POS, while synergy between lonafarnib and VRC was much less observed in both species. It's notable that although Aspergillus isolates exhibited higher MIC values to ITC than to POS or VRC, synergistic effects were most often observed between lonafarnib and ITC. Lonafarnib was originally designed to be an antitumor agent. Although it has been shown to have limited effects in solid tumors, lonafarnib shows potential as a combination therapy in hematological malignancies. 20 Patients with hematological malignancies are particularly predisposed to opportunistic fungal infections, and it is beneficial to select a therapeutic regimen that has a potential to enhance the activity of antifungal azoles without antagonism. Additionally, other important effects of lonafarnib, including antiangiogenic effects, pro-apoptotic effect against human cells, were revealed in several studies. 21, 22 The interactions of lonafarnib and azoles might be associated with the effects of lonafarnib on membrane protein interactions, and the pro-apoptotic effects, the latter of which would need further investigations to prove. Interestingly, lonafarnib showed predilection to synergize with ITC and POS instead of VRC. POS is derived from ITC and shares a similar structure of long hydrophobic aliphatic side chain with ITC, while VRC lacks. These might in part explain the disparity of interaction profiles between the three azoles and lonafarnib. However, the underlying mechanism of lonafarnib synergizing with azoles remains to be elucidated.
Lonafarnib has demonstrated excellent pharmacokinetic and safety profile. At the recommended once daily continuous monotherapy dose of 300 mg, trough plasma concentrations of lonafarnib exceed 1.5 μM (0.96 μg/ml). 23 The peak plasma concentrations increase approximately two-to fivefold on repeated dosing in a dose-independent manner, 24 suggesting that the effective working range of lonafarnib in combination with azoles could possibly be achieved. Lonafarnib causes manageable side effects, among which the most frequent are fatigue, diarrhea, nausea, and anorexia. 23, 24 In conclusion, the present study expanded our knowledge of the interactions between FTIs and conventional antifungals. Lonafarnib could enhance the in vitro antifungal activities of azoles against Aspergillus and E. dermatitidis isolates, especially ITC and POS, suggesting that FTIs might prove an important partner in combined therapies with azoles. However, modification of FTIs is required for optimal antifungal efficiency. Further studies are needed to elucidate the potential clinical use and to develop fungi specific FTIs without collateral effects on human cells.
